Ask the expert: How to spot fake Parkinson’s medicines online
Author: Caithlin NgPublished: 27 February 2020
Prep: Cook: Serves:
In the third in our expert series, we talk to Mike Isles, Executive Director of the Alliance for Safe Online Pharmacy in the EU, about the growing problem of fake Parkinson’s medicines advertised and sold online – from their shocking prevalence to top tips on how to stay safe
Firstly, could you explain to our readers what falsified medicines are?
Falsified, fake or counterfeit medicines are medicines disguising themselves as authentic. They can pose significant health risks and might contain ingredients that are of bad or toxic quality, or they might provide the wrong dosage of active ingredients or an altogether different product. They haven’t been checked for quality, safety and efficacy against the EU’s strict regulations for healthcare products, making them a real risk to your health.
You work for the Alliance for Safe Online Pharmacy. What is it and what are its key aims?
The Alliance for Safe Online Pharmacy (ASOP EU) was created in 2011 to raise public awareness about the growing problem of falsified medicines online for European patients. ASOP EU works to encourage development and maintenance of a safe and secure environment in which patients and caregivers may access medications online, if they so choose. This is a complex problem that requires a multifactorial approach – criminals are offering falsified medicines to European citizens on not just 35,000 illegally operating websites, but also through social media and e-commerce platforms.
How common are falsified Parkinson’s medications?
It is difficult to pinpoint the number of websites offering Parkinson’s medications online, but law enforcement officials around the world take down websites and seize packages – many thousands – with falsified medicines every year, including neurological medicines and other highly-coveted prescription drugs. It is clear that if there is a market for a medication, criminals will want to produce falsified versions to meet it. These illegal actors will place any potential profits above public health and patient safety, especially in areas where there is consumer demand.
What are some actions that policymakers can take?
The Falsified Medicines Directive has been an excellent lever for helping to secure the legitimate supply chain – this comprises the manufacturer, wholesaler, pharmacist and patient. However, the illegal online pharmacy websites operate outside of the highly-regulated bricks-and-mortar supply chain, so governments should look at the various points of entry that use the internet to ensure they are operating safely for the public.
How aware are people of these scams?
Ninety-six per cent of websites selling medicine are operating illegally, but a survey from ASOP EU’s website found that on average just over 50% of people are unaware of this. Having recognised the pervasive threat of illegal online drug sellers a very high proportion, in fact greater than 90%, indicated a potential change in their behaviour, such as seeking out a bricks-and-mortar pharmacy or an authentic internet pharmacy. Our educational approach appears to be working.
What are your top tips for the Parkinson’s community to safely buy medicine online?
The best tip to avoid buying medicine
from an illegal online pharmacy is to verify three main items: a licensed
pharmacist present on site, a physical address for operations, and a working
telephone number. Patients should be wary of websites that offer bulk discounts,
too-good-to-be-true prices, or outrageous results, and very importantly that do
not require a valid prescription.
Under the EU’s Falsified Medicines Directive, any retailer in a member state must also register with their local health authority to sell medicine online; they are then legally obliged to put a “common logo” on their website. In the UK, patients can check whether the seller is registered on the Medicines and Healthcare products Regulatory Agency website.
Who can the public consult if they are still unsure?
The first port of call should be their
pharmacist or other healthcare provider, who will be knowledgeable about the
situation. Because falsified medicines sold online are designed to look as much
as possible like the original product, it can be virtually impossible to tell
the difference. It is also important not to be duped into thinking that
medicines with no legitimate product licence for use in EU member states –
therefore accompanied by insufficient clinical evidence – will work and have
In addition ASOP EU and its sister non-profit organisation ASOP Global has a wealth of information about this important area, which can be found at buysaferx.pharmacy.
There are lots of people in this world who are not aware of the rigorous clinical tests to prove safety and effectiveness before a medicine receives its licence – and so people can be very vulnerable and willing to try anything because conventional medicine isn’t working or has become unaffordable.
Need to know: Mike Isles is Executive Director of the Alliance for Safe Online
Pharmacy in the EU, an organisation addressing the threat of illegal online
drug sales. He has had a long career in the pharmaceuticals industry and has
since spent the last 10 years devoting his time to patient safety issues.
At a glance: fake medicines online
Fake medicines, which can pose significant health risks, are sold on around 35,000 websites and via social media and e-commerce platforms.
96% of websites selling medicines operate illegally – but a survey suggests that over 50% of people are not aware of this.
It can be difficult to see the difference between fake and authentic medicines, as they are designed to look similar.
Internet users should confirm that an online pharmacy lists a licensed pharmacist, a physical operational address, a working telephone number and requires a valid prescription before placing an order.
Painter with Parkinson’s: John McLean shares some of his favourite works
From large stained-glass windows to abstract explosions of colour
6 days ago
A “revolutionary” step in stem cell therapy for Parkinson’s disease?
Scientists in China have developed a method to help improve stem cell research in mice models of Parkinson’s – which could potentially lead to promising new treatments. The researchers, based at the Chinese Academy of Sciences, identified two cell surface markers of dopamine neurons, which are reduced in Parkinson’s. They injected cells with these markers into the brains of the mice and found that this resulted in “higher therapeutic potency” for improving motor symptoms of the condition. As part of their research, the team also worked to control the variability of donor cells, to help improve therapeutic outcomes for Parkinson’s cell therapy. The researchers, whose study was published in ‘The Journal of Clinical Investigation’, described the findings as a “revolutionary step on the road towards more effective and safer stem cell therapies”.
Could frequent nightmares be an early sign of Parkinson’s disease?
A new study has suggested that experiencing recurrent nightmares and bad dreams could be an early symptom of Parkinson’s disease. Researchers from the University of Birmingham, UK, used data from an existing US study that followed 3818 men, aged 67 or older, over a period of 12 years. Participants who reported experiencing bad dreams at least once a week were followed up. During the follow up, 91 people were diagnosed with Parkinson’s. The results suggested that participants who had frequent bad dreams were twice as likely to develop the condition as those who did not. Commenting on the study, lead author Dr Abidemi Otaiku said: “While we need to carry out further research, identifying the significance of bad dreams and nightmares could indicate that individuals who experience changes to their dreams in older age – without any obvious trigger – should seek medical advice.”
More than £2m awarded to research on mitochondria and Parkinson’s disease
Researchers at UK biotech startup NRG Therapeutics are developing potential treatments that may help slow the progression of Parkinson’s by protecting the mitochondria – a part of every human cell that works to power chemical reactions. The company has now received a £2.68m award from government-backed agency Innovate UK to continue its research. Their research built upon previous findings that damage to mitochondria in the substantia nigra – an area of the brain associated with dopamine – may be linked to Parkinson’s. The scientists developed molecules that keep a ‘pore’ in the mitochondria closed, which stops calcium flowing into it, preventing a process that eventually ruptures the powerhouse of the cell and leads to its death. The new funding award follows previous investment from Parkinson’s UK and the Michael J Fox Foundation.